There is a version of this decision where you are choosing between medicating your child and being a better parent, and it is the version almost everybody arrives with. The research does not describe that choice. It describes two things that do different jobs, one age band where the order is clearly specified, and a long-term picture that is more uncertain than either camp admits.

The short answer: the guideline answer depends on your child's age. For four- and five-year-olds, behavioural parent training is the first-line treatment, with methylphenidate considered only if that does not help enough and the disturbance is moderate to severe. From six to eleven, the recommendation is medication together with parent training and classroom support — preferably both. From twelve to seventeen, medication with the adolescent's own assent. The evidence behind it is genuinely strong over weeks and months, and genuinely thin past a year: the largest network meta-analysis, 133 trials, states outright that it found insufficient data at the 26- and 52-week points. And the landmark trial found the advantage from fourteen months of assigned treatment had disappeared by three years and again at eight. None of that means medication does not work. It means the question is not "should we" but "for what, for how long, and how will we know."¹ ² ³ ⁴

What the guideline actually says, by age

The three recommendations, quoted, because consumer summaries routinely reverse them:¹

Ages 4 to 5: "the PCC should prescribe evidence-based behavioral PTBM and/or behavioral classroom interventions as the first line of treatment, if available (grade A: strong recommendation). Methylphenidate may be considered if these behavioral interventions do not provide significant improvement and there is moderate-to-severe continued disturbance in the 4-through 5-year-old child's functioning."

Ages 6 to 11: "the PCC should prescribe US Food and Drug Administration (FDA)–approved medications for ADHD, along with PTBM and/or behavioral classroom intervention (preferably both)." Both parts carry a grade A strong recommendation.

Ages 12 to 17: "the PCC should prescribe FDA-approved medications for ADHD with the adolescent's assent (grade A: strong recommendation)."

And at both school ages: "Educational interventions and individualized instructional supports… are a necessary part of any treatment plan and often include an IEP or a rehabilitation plan (504 plan)."¹

So the "try everything else first" instinct matches the guideline exactly — for preschoolers. From six upward the guideline does not treat medication and behavioural work as alternatives; it asks for both.

One oddity worth knowing for the preschool band. Amphetamine is the only ADHD drug with a US approval below age six, from age three — but the guideline notes that authorisation "was issued at a time when approval criteria were less stringent than current requirements," and its own named option for four- and five-year-olds is methylphenidate, which is off-label there.¹ And in 2025 the FDA required expanded labelling stating that "the benefits of extended-release stimulants may not outweigh the risks of these products in patients younger than 6 years with ADHD," noting higher plasma exposures and higher rates of side effects at that age.⁵

What the medications do

The network meta-analysis pooled 133 double-blind randomised trials, with 10,068 children and adolescents in the efficacy analysis.²

Drug Clinician-rated effect versus placebo, children and adolescents
Amphetamines SMD −1.02 (95% CI −1.19 to −0.85)
Methylphenidate SMD −0.78 (−0.93 to −0.62)
Atomoxetine SMD −0.56 (−0.66 to −0.45)

Those are large effects by the standards of psychiatry. Three qualifications belong with them.

Teachers saw less. "for available comparisons based on teachers' ratings, only methylphenidate (SMD -0·82, 95% CI -1·16 to -0·48) and modafinil (-0·76, -1·15 to -0·37) were more efficacious than placebo."² Whose rating you use changes the answer.

Tolerability runs the other way. Amphetamines were worse tolerated than placebo in children (odds ratio 2.30), as was guanfacine (2.64).² The review's first-choice recommendation for this age group — "evidence from this meta-analysis supports methylphenidate in children and adolescents… as preferred first-choice medications for the short-term treatment of ADHD" — rests on that trade-off, not on methylphenidate being the strongest.²

And the evidence stops early. In the authors' words: "We did not find sufficient data for the 26-week and 52-week timepoints."² Everything above describes roughly twelve weeks.

What the long trial found, and how to read it

The Multimodal Treatment Study randomised 579 children aged 7 to 9.9 to fourteen months of medication management, intensive behavioural treatment, both, or community care.³

Fourteen months (randomised). Medication management and combined treatment beat behavioural treatment and community care on ADHD symptoms; combined treatment showed extra benefit on oppositional and internalising symptoms, social skills, parent–child relations and reading. The comparison group was not untreated — "two thirds of community-treated subjects received medication during the study period."³

Twenty-four months. The advantage persisted but "the effect size was reduced by 50% from the end of treatment to the first follow-up."⁶

Thirty-six months. "treatment groups did not differ significantly on any measure at 36 months," in a cohort where the behavioural arm had gone from 14 to 45 percent medicated and the medication arms from 91 to 71 percent. The authors' candidate explanations: "age-related decline in ADHD symptoms, changes in medication management intensity, starting or stopping medications altogether, or other factors not yet evaluated."⁴

Six to eight years. "Type or intensity of 14 months of treatment for ADHD in childhood… does not predict functioning 6 to 8 years later. Rather, early ADHD symptom trajectory regardless of treatment type is prognostic."⁷

Neither camp gets to keep this study. It is not evidence that medication stops working — the randomised phase ended at fourteen months and everything after it is a naturalistic follow-up with heavy crossover in both directions. It is evidence that a period of good treatment in childhood does not, by itself, buy a different adolescence, which is an argument for treating ADHD as an ongoing condition to be managed and reviewed rather than a course to complete.

The finding that sits on the other side

Large studies that compare people to themselves during medicated and unmedicated months — a design that removes stable differences between people — find substantially lower rates of specific acute harms while treated:

  • Motor vehicle crashes, across 2,319,450 US patients: 38 percent lower risk in males and 42 percent lower in females during medicated months, with the authors estimating that "up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up."⁸
  • Criminal convictions, in 25,656 Swedish patients: "a significant reduction of 32% in the criminality rate for men… and 41% for women" during medicated periods.⁹
  • Mortality, in 148,578 people: medication initiation "was associated with significantly lower rate of all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.70 to 0.88)."¹⁰

These are observational and cannot fully exclude confounding by why people take medication when they do. They also answer a different question from the MTA's. Does treating a child for fourteen months change their life at sixteen? Apparently not. Is a person measurably safer during a month when they are treated? On this evidence, yes.

The worries, answered with the data

Growth. Real, modest, and usually reported at the wrong magnitude. The full growth answer →

Substance use later. Looked at directly in the MTA cohort: "no evidence that stimulant treatment was associated with increased or decreased risk for later frequent use of alcohol, marijuana, cigarette smoking, or other substances used for adolescents and young adults with childhood ADHD."¹¹

Personality change. Not what titration is aiming at. The guideline's instruction is to "titrate doses of medication for ADHD to achieve maximum benefit with tolerable side effects."¹ A child who seems flattened, tearful or robotic is a child whose dose or drug needs revisiting, and that is a clinical adjustment rather than the price of treatment.

"Are we just medicating them for the school's convenience?" A fair question, and the honest reply is that the evaluation should have documented impairment "in more than 1 major setting"¹ — so if the difficulty exists only in one classroom, that is worth saying out loud. So is your child's age within the year. What else looks like ADHD →

The six questions to ask

  1. "What are we treating, specifically?" Name two or three concrete things — finishing a worksheet, getting out of the house, not losing friendships — rather than a score.
  2. "What would count as it working, and when do we check?" Agree a review date before the first dose. Ask for teacher ratings as well as your own; the trials show the two diverge.²
  3. "What is the titration plan?" The guideline asks for titration "to achieve maximum benefit with tolerable side effects," which means starting low and adjusting, not one prescription and a year of silence.¹
  4. "What will we monitor?" Height and weight at minimum, plus sleep and appetite. Growth →
  5. "What is the behavioural and school half of the plan?" From age six the guideline recommends both, and the educational supports are described as necessary rather than optional.¹ Parent training → · Request a school assessment →
  6. "How do we stop, if we want to?" A planned trial off medication — at a time that is not the week of exams — is a reasonable thing to ask for, and a reasonable thing for a clinician to agree.

Bring the answers home in writing. The printable evaluation prep →

If you decide not to, or not yet

That is a legitimate decision, and it is worth making an active one rather than a default. Two things make it a better one.

Take the behavioural half seriously, on what it actually does. Under blinded measurement, parent training improves parenting quality (standardised mean differences 0.63 and 0.43) and child conduct problems (0.31); it does not show a blinded effect on ADHD symptoms themselves.¹² Fewer fights and a calmer household is a large gain, and it is the gain that is real. What parent training does →

And be careful with the alternatives, most of which look effective only when the person rating the child knows what was tried. Does neurofeedback work? →

Set a date to revisit. Six months is reasonable. Deciding not to medicate is not a decision that has to be permanent, and neither is the reverse.

Q&A

Q: At what age can a child take ADHD medication? A: In the US, amphetamine carries an approval from age 3 and most other ADHD medications from age 6.⁵ The guideline recommends behavioural treatment first for ages 4 to 5, with methylphenidate — off-label at that age — considered if behavioural treatment is not enough.¹

Q: Does medication have to be forever? A: No, and it very often is not. In the sixteen-year MTA follow-up, most participants had fluctuating periods of remission and recurrence rather than a fixed course.¹³ Planned reviews, including planned trials off medication, are a normal part of managing it.

Q: Is it addictive? A: Stimulants are controlled substances and the prescribing rules reflect that. On the specific fear that treating a child leads to later substance problems, the MTA looked and found no association in either direction.¹¹

Q: My child is only struggling at school, not at home. A: Worth saying to the clinician plainly. The diagnosis requires documented impairment in more than one setting, and a single-setting difficulty may point at the setting.¹

Q: What if we try it and it doesn't help? A: Then it is information, and titration or a different medication is the usual next step; the network meta-analysis found real differences between drugs.² Not responding to one is not a verdict on all of them.

Q: Can we do therapy instead? A: For ages 4 to 5, that is exactly what the guideline recommends first.¹ From six upward it recommends both together, and the blinded evidence for behavioural interventions is on parenting and conduct rather than on ADHD symptoms.¹²

Ready to find a clinician who will answer these six questions? Filter by approach, schedule and payment route → · ADHD in children: the parent map → · ADHD therapy: what actually works →

In crisis? Call or text 988 — free, 24/7.

Sources

  1. Wolraich ML, Hagan JF Jr, Allan C, et al., "Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents," Pediatrics 144(4), 2019, e20192528 — key action statements 2, 5a, 5b, 5c and 6, quoted; and the note on the amphetamine paediatric authorisation — pmc.ncbi.nlm.nih.gov.
  2. Cortese S, Adamo N, Del Giovane C, et al., "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis," The Lancet Psychiatry 5(9), 2018, 727–738 — 133 trials; effect sizes by drug and rater; tolerability odds ratios; "evidence from this meta-analysis supports methylphenidate in children and adolescents… as preferred first-choice medications for the short-term treatment of ADHD"; "We did not find sufficient data for the 26-week and 52-week timepoints" — pmc.ncbi.nlm.nih.gov.
  3. MTA Cooperative Group, "A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder," Archives of General Psychiatry 56(12), 1999, 1073–1086 — the four arms and 579 children aged 7 to 9.9; "two thirds of community-treated subjects received medication during the study period" — doi.org.
  4. Jensen PS, Arnold LE, Swanson JM, et al., "3-year follow-up of the NIMH MTA study," Journal of the American Academy of Child and Adolescent Psychiatry 46(8), 2007, 989–1002 — "treatment groups did not differ significantly on any measure at 36 months"; the crossover figures and the authors' candidate explanations — doi.org.
  5. US Food and Drug Administration, "FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants," drug safety communication, 30 June 2025 — "the benefits of extended-release stimulants may not outweigh the risks of these products in patients younger than 6 years with ADHD" — fda.gov; Adderall prescribing information, revised October 2023 — accessdata.fda.gov.
  6. MTA Cooperative Group, "National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment," Pediatrics 113(4), 2004, 762–769 — "the effect size was reduced by 50% from the end of treatment to the first follow-up" — doi.org.
  7. Molina BSG, Hinshaw SP, Swanson JM, et al., "The MTA at 8 years," Journal of the American Academy of Child and Adolescent Psychiatry 48(5), 2009, 484–500 — "Type or intensity of 14 months of treatment for ADHD in childhood… does not predict functioning 6 to 8 years later" — pmc.ncbi.nlm.nih.gov.
  8. Chang Z, Quinn PD, Hur K, et al., "Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes," JAMA Psychiatry 74(6), 2017, 597–603 — 2,319,450 patients; "up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up" — pmc.ncbi.nlm.nih.gov.
  9. Lichtenstein P, Halldner L, Zetterqvist J, et al., "Medication for attention deficit-hyperactivity disorder and criminality," New England Journal of Medicine 367(21), 2012, 2006–2014 — pmc.ncbi.nlm.nih.gov.
  10. Li L, Zhu N, Zhang L, et al., "ADHD pharmacotherapy and mortality in individuals with ADHD," JAMA 331(10), 2024, 850–860 — pmc.ncbi.nlm.nih.gov.
  11. Molina BSG, Kennedy TM, Howard AL, et al., "Association between stimulant treatment and substance use through adolescence into early adulthood," JAMA Psychiatry 80(9), 2023, 933–941 — doi.org.
  12. Daley D, van der Oord S, Ferrin M, et al., "Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains," Journal of the American Academy of Child and Adolescent Psychiatry 53(8), 2014, 835–847 — "With probably blinded assessments, significant effects persisted for parenting (SMD for positive parenting 0.63; SMD for negative parenting 0.43) and conduct problems (SMD 0.31)" — doi.org.
  13. Sibley MH, Arnold LE, Swanson JM, et al., "Variable patterns of remission from ADHD in the Multimodal Treatment Study of ADHD," American Journal of Psychiatry 179(2), 2022, 142–151 — "Most participants with ADHD (63.8%) had fluctuating periods of remission and recurrence over time" — pmc.ncbi.nlm.nih.gov.

Paid for by participating therapists. Inclusion is computed from availability data — never purchased. No ads, no data sold.